Ladenburg analyst Matthew Kaplan lowered the firm’s price target on United Therapeutics to $285 from $295 and keeps a Buy rating on the shares following the Q4 results. The analyst expects the growth of treprostinil-based products to largely be driven by the growing market potential for Tyvaso. The decreased price target reflects updated projections for United’s pipeline programs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on UTHR: